These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 26678339)

  • 1. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.
    Tateishi K; Wakimoto H; Iafrate AJ; Tanaka S; Loebel F; Lelic N; Wiederschain D; Bedel O; Deng G; Zhang B; He T; Shi X; Gerszten RE; Zhang Y; Yeh JJ; Curry WT; Zhao D; Sundaram S; Nigim F; Koerner MVA; Ho Q; Fisher DE; Roider EM; Kemeny LV; Samuels Y; Flaherty KT; Batchelor TT; Chi AS; Cahill DP
    Cancer Cell; 2015 Dec; 28(6):773-784. PubMed ID: 26678339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism: Totally addicted to NAD(.).
    Shipman L
    Nat Rev Cancer; 2016 Feb; 16(2):70. PubMed ID: 26743031
    [No Abstract]   [Full Text] [Related]  

  • 3. The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in
    Tateishi K; Higuchi F; Miller JJ; Koerner MVA; Lelic N; Shankar GM; Tanaka S; Fisher DE; Batchelor TT; Iafrate AJ; Wakimoto H; Chi AS; Cahill DP
    Cancer Res; 2017 Aug; 77(15):4102-4115. PubMed ID: 28625978
    [No Abstract]   [Full Text] [Related]  

  • 4. Different Effects of RNAi-Mediated Downregulation or Chemical Inhibition of NAMPT in an Isogenic IDH Mutant and Wild-Type Glioma Cell Model.
    Clausing M; William D; Preussler M; Biedermann J; Grützmann K; Richter S; Buchholz F; Temme A; Schröck E; Klink B
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.
    Machida Y; Nakagawa M; Matsunaga H; Yamaguchi M; Ogawara Y; Shima Y; Yamagata K; Katsumoto T; Hattori A; Itoh M; Seki T; Nishiya Y; Nakamura K; Suzuki K; Imaoka T; Baba D; Suzuki M; Sampetrean O; Saya H; Ichimura K; Kitabayashi I
    Mol Cancer Ther; 2020 Feb; 19(2):375-383. PubMed ID: 31727689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma.
    Peterse EFP; van den Akker BEWM; Niessen B; Oosting J; Suijker J; de Jong Y; Danen EHJ; Cleton-Jansen AM; Bovée JVMG
    Mol Cancer Res; 2017 Dec; 15(12):1714-1721. PubMed ID: 28860121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
    Cea M; Cagnetta A; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Roccaro A; Sacco A; Calimeri T; Cottini F; Jakubikova J; Kong SY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC
    Blood; 2012 Oct; 120(17):3519-29. PubMed ID: 22955917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit.
    Kopinja J; Sevilla RS; Levitan D; Dai D; Vanko A; Spooner E; Ware C; Forget R; Hu K; Kral A; Spacciapoli P; Kennan R; Jayaraman L; Pucci V; Perera S; Zhang W; Fischer C; Lam MH
    Sci Rep; 2017 Oct; 7(1):13853. PubMed ID: 29062039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation.
    Wen F; Gui G; Wang X; Qin A; Ma T; Chen H; Li C; Zha X
    J Med Chem; 2024 Jun; 67(11):8667-8692. PubMed ID: 38651495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
    Pusch S; Krausert S; Fischer V; Balss J; Ott M; Schrimpf D; Capper D; Sahm F; Eisel J; Beck AC; Jugold M; Eichwald V; Kaulfuss S; Panknin O; Rehwinkel H; Zimmermann K; Hillig RC; Guenther J; Toschi L; Neuhaus R; Haegebart A; Hess-Stumpp H; Bauser M; Wick W; Unterberg A; Herold-Mende C; Platten M; von Deimling A
    Acta Neuropathol; 2017 Apr; 133(4):629-644. PubMed ID: 28124097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration.
    Cao H; Zhu G; Sun L; Chen G; Ma X; Luo X; Zhu J
    Eur J Med Chem; 2019 Dec; 183():111694. PubMed ID: 31561044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AMP kinase promotes glioblastoma bioenergetics and tumour growth.
    Chhipa RR; Fan Q; Anderson J; Muraleedharan R; Huang Y; Ciraolo G; Chen X; Waclaw R; Chow LM; Khuchua Z; Kofron M; Weirauch MT; Kendler A; McPherson C; Ratner N; Nakano I; Dasgupta N; Komurov K; Dasgupta B
    Nat Cell Biol; 2018 Jul; 20(7):823-835. PubMed ID: 29915361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NAD
    Moore AM; Zhou L; Cui J; Li L; Wu N; Yu A; Poddar S; Liang K; Abt ER; Kim S; Ghukasyan R; Khachatourian N; Pagano K; Elliott I; Dann AM; Riahi R; Le T; Dawson DW; Radu CG; Donahue TR
    Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33597293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the vulnerability to NAD
    Takao S; Chien W; Madan V; Lin DC; Ding LW; Sun QY; Mayakonda A; Sudo M; Xu L; Chen Y; Jiang YY; Gery S; Lill M; Park E; Senapedis W; Baloglu E; Müschen M; Koeffler HP
    Leukemia; 2018 Mar; 32(3):616-625. PubMed ID: 28904384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL.
    Karpel-Massler G; Ishida CT; Bianchetti E; Zhang Y; Shu C; Tsujiuchi T; Banu MA; Garcia F; Roth KA; Bruce JN; Canoll P; Siegelin MD
    Nat Commun; 2017 Oct; 8(1):1067. PubMed ID: 29057925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells.
    Hujber Z; Petővári G; Szoboszlai N; Dankó T; Nagy N; Kriston C; Krencz I; Paku S; Ozohanics O; Drahos L; Jeney A; Sebestyén A
    J Exp Clin Cancer Res; 2017 Jun; 36(1):74. PubMed ID: 28578659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.
    Andronesi OC; Arrillaga-Romany IC; Ly KI; Bogner W; Ratai EM; Reitz K; Iafrate AJ; Dietrich J; Gerstner ER; Chi AS; Rosen BR; Wen PY; Cahill DP; Batchelor TT
    Nat Commun; 2018 Apr; 9(1):1474. PubMed ID: 29662077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
    Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH
    Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
    O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D
    Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Energy Metabolism in
    van Noorden CJF; Hira VVV; van Dijck AJ; Novak M; Breznik B; Molenaar RJ
    Cells; 2021 Mar; 10(3):. PubMed ID: 33810170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.